Prolactin receptor does not correlate with oestrogen and progesterone receptors in primary breast cancer and lacks prognostic significance. Ten year results of the Naples adjuvant (GUN) study.
Prolactin receptor does not correlate with oestrogen and progesterone receptors in primary breast cancer and lacks prognostic significance. Ten year results of the Naples adjuvant (GUN) study.
复制标题
催乳素受体与原发性乳腺癌中的雌激素和孕激素受体不相关，缺乏预后意义。
作者：
S. Placido;Ciro Gallo;Francesco Perrone;A. Marinelli;C. Pagliarulo;C. Carlomagno;G. Petrella;Michela d'Istria;G. Delrio;A. Bianco
在那不勒斯（GUN）辅助试验中，研究了乳腺癌中催乳素（PRLR）与雌激素（ER）或孕激素受体（PgR）之间的相关性以及PRLR在10年随访时可能的预后意义。从1978年2月1日至1983年12月31日，共有308名绝经前和绝经后早期乳腺癌患者进入试验，随机接受他莫昔芬（TM），30 mg/例，持续2年，或不治疗。229例（74.3%）患者的PRLR状态已知。特异性结合小于1%的值视为阴性。PRLR阳性75/229（32.8%）。210/229例（91.7%）患者检测了ER，188/229例（82.1%）患者检测了PgR。经斯皮尔曼检验，PRLR与ER、PgR之间无显著相关性，而ER状态与PgR状态高度相关。通过考克斯模型，未观察到PRLR对无病生存期（DFS）的独立预后作用的证据，也未发现PRLR与TM辅助治疗之间的相互作用。
The correlation between prolactin (PRLR) and oestrogen (ER) or progesterone receptors (PgR) in breast cancer and a possible prognostic significance of PRLR at 10 year follow-up have been investigated in the Naples (GUN) adjuvant trial. A total of 308 pre- and post-menopausal patients with early breast cancer, who entered the trial from 1 February 1978 to 31 December 1983, received randomly Tamoxifen (TM), 30 mg per die for 2 years, or no therapy. PRLR status was known in 229 (74.3%) patients. Values of specific binding less than 1% were considered negative. PRLR was positive in 75/229 (32.8%). ER was assayed in 210/229 (91.7%) patients and PgR in 188/229 (82.1%). No significant correlation, by the Spearman test, was found between PRLR and ER or PgR, while ER status was highly interrelated with PgR status. By the Cox model no evidence of an independent prognostic role of PRLR on disease-free survival (DFS) was observed, nor an interaction between PRLR and adjuvant treatment with TM was found.
催乳素在大鼠乳腺肿瘤 MTW9 生长中的作用。
影响因子：
6.4
作者：
Platica,M;Doody,J;Mandeli,JP;Hollander,VP
通讯作者：
Hollander,VP
催乳素受体的特征及其在美国和以色列乳腺癌女性中的分布：对预测激素依赖性和治疗的影响。
DOI：
--
发表时间：
1988
期刊：
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
影响因子：
--
作者：
Ben-David,M;Kadar,T;Wittliff,J;Biran,S;Schally,A
通讯作者：
Schally,A
乳腺癌女性催乳素受体和类固醇受体水平之间缺乏相关性。
DOI：
--
发表时间：
1988
期刊：
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
影响因子：
--
作者：
Ben-David,M;Wittliff,JL;Fekete,M;Kadar,T;Biran,S;Schally,AV
通讯作者：
Schally,AV